Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics

References

• Brooks AN, Kilgour E, Smith PD. Molecular Pathways. Fibroblast growth factor signaling. a new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18(7):1855-62; PMID:22388515; http://dx.doi.org/10.1158/1078-0432.CCR-11-0699
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway. opportunities for targeted therapies in solid tumors. Ann Oncol 2014; 25(3):552-63; PMID:24265351; http://dx.doi.org/10.1093/annonc/mdt419
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signaling. from development to cancer. Nat Rev Cancer 2010; 10:116-29; PMID:20094046; http://dx.doi.org/10.1038/nrc2780
   PubMed Web of Science ®Google Scholar
• Nie X, Luukko K, Kettunen P. FGF signaling in craniofacial development and developmental disorders. Oral Dis 2006; 12(2):102-11; PMID:16476029; http://dx.doi.org/10.1111/j.1601-0825.2005.01176.x
   PubMed Web of Science ®Google Scholar
• Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. the complete mammalian FGF family. J Biol Chem 2006; 281:15694-700; PMID:16597617; http://dx.doi.org/10.1074/jbc.M601252200
   PubMed Web of Science ®Google Scholar
• Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-78; PMID:15863032; http://dx.doi.org/10.1016/j.cytogfr.2005.01.004
   PubMed Web of Science ®Google Scholar
• Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437:199-213; PMID:21711248; http://dx.doi.org/10.1042/BJ20101603
   PubMed Web of Science ®Google Scholar
• Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. J Canc Res 2000; 60(15):4245-50
   Google Scholar
• Itoh N, Ornitz D. Evolution of the FGF and FGFR gene families. Trends Genet 2004; 20:563-9;; PMID:15475116; http://dx.doi.org/10.1016/j.tig.2004.08.007
   PubMed Web of Science ®Google Scholar
• Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013; 57(4):1407-15; PMID:22890726; http://dx.doi.org/10.1002/hep.25956
   PubMed Web of Science ®Google Scholar
• Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, Bianciotto M et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 2013; 23(4):477-88; PMID:23597562; http://dx.doi.org/10.1016/j.ccr.2013.02.019
   PubMed Web of Science ®Google Scholar
• Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF. inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17(19):6130-9; PMID:21953501; http://dx.doi.org/10.1158/1078-0432.CCR-11-0659
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013; 340:97-103; PMID:23856031; http://dx.doi.org/10.1016/j.canlet.2013.07.007
   PubMed Web of Science ®Google Scholar
• Soria J, DeBraud F, Bahleda R, Adamo B, Andre F, Dientsmann R, Delmonte A, Cereda R, Isaacson J, Litten J et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 2014; 25:2244-51; PMID:25193991; http://dx.doi.org/10.1093/annonc/mdu390
   PubMed Web of Science ®Google Scholar
• Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R, Michaelson MD. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol 2013; 73:181-9; PMID:24190702; http://dx.doi.org/10.1007/s00280-013-2339-y
   PubMed Web of Science ®Google Scholar
• Capdevila J, Dienstmann R, Adamo B, Cereda R, Litten J, Collin J, Legrand F, Robert R, Saba C, De Braud FGM et al. Prolonged anti-tumor activity of lucitanib in advanced thyroid cancer. Ann Oncol 2014; 25(suppl 4):iv340-56
   Google Scholar
• Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ et al. AZD4547; an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72(8):2045-56; PMID:22369928; http://dx.doi.org/10.1158/0008-5472.CAN-11-3034
   PubMed Web of Science ®Google Scholar
• Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010; 70(10):4151-62; PMID:20460524; http://dx.doi.org/10.1158/0008-5472.CAN-09-4479
   PubMed Web of Science ®Google Scholar
• Elsheikh ES, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, Reis-Filho JS. FGFR1 amplification in breast carcinomas. a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9(2):R23; PMID:17397528; http://dx.doi.org/10.1186/bcr1665
   PubMed Web of Science ®Google Scholar
• Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002; 2:301-14; PMID:12398894; http://dx.doi.org/10.1016/S1535-6108(02)00150-2
   PubMed Web of Science ®Google Scholar
• Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70:2085-94; PMID:20179196; http://dx.doi.org/10.1158/0008-5472.CAN-09-3746
   PubMed Web of Science ®Google Scholar
• Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008; 10:847-56; PMID:18670643; http://dx.doi.org/10.1593/neo.08450
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos M, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2(62):62ra93; PMID:21160078; http://dx.doi.org/10.1126/scitranslmed.3001451
   PubMed Web of Science ®Google Scholar
• Koziczak M, Holbro T, Hynes N. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004; 23:3501-8; PMID:15116089; http://dx.doi.org/10.1038/sj.onc.1207331
   PubMed Web of Science ®Google Scholar
• Hynes N, Dey J. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 2010; 70:5199-202; PMID:20570901; http://dx.doi.org/10.1158/0008-5472.CAN-10-0918
   PubMed Web of Science ®Google Scholar
• Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008; 14:8000-9; PMID:19088016; http://dx.doi.org/10.1158/1078-0432.CCR-08-0975
   PubMed Web of Science ®Google Scholar
• Singh D, Chan J, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337:1231-5; PMID:22837387; http://dx.doi.org/10.1126/science.1220834
   PubMed Web of Science ®Google Scholar
• Guancial E, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz F, Park R, O'Brein R, Hirsch M et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med 2014; 3:835-44; PMID:24846059; http://dx.doi.org/10.1002/cam4.262
   PubMed Web of Science ®Google Scholar
• Foldynova-Trantirkova S, Wilcox W, Krejci P. Sixteen years and counting. The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat 2011; 33:29-41; PMID:22045636; http://dx.doi.org/10.1002/humu.21636
   PubMed Web of Science ®Google Scholar
• Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker B, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget 2015; 6(5):3033-42; PMID:25596748
   PubMed Web of Science ®Google Scholar
• Simon R, Bürger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998; 185:345-51; PMID:9828832; http://dx.doi.org/10.1002/(SICI)1096-9896(199808)185:4%3c345::AID-PATH109%3e3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Dellas A, Torhorst J, Jiang F, Proffitt J, Schultheiss E, Holzgreve W, Sauter G, Mihatsch MJ, Moch H. Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization. Cancer Res 1999; 59:3475-9; PMID:10416613
   PubMed Web of Science ®Google Scholar